Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 9008 results

  1. Electrosurgery (diathermy and coblation) for tonsillectomy

    Topic prioritisation

  2. Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

    Topic prioritisation

  3. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

  4. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

  5. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

  6. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

  7. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

  8. Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]

    Topic prioritisation

  9. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

  10. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

  11. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

  12. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

  13. Head injury (QS74) update: topic engagement

    We are listening to your views on this Quality standard. Comments close 30 April 2026.

  14. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

  15. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC